<?xml version='1.0'?><!DOCTYPE Annotation PUBLIC "//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN_Modified" "../ModifiedGENIAtypes/Modified_GENIA_event_20.dtd"><Annotation annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=9756417" created="04/05/2006" creator="Noriko Katsu"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>9756417</PMID>
<Article>
<ArticleTitle>
<sentence id="S1"><term id="T1" lex="transcription_factor_activation" sem="Other"><term id="T2" lex="transcription_factor" sem="Protein_family_or_group">Transcription factor</term> activation</term> in <term id="A1" sem="Protein_molecule">lymphokine</term> activated <term id="T3" lex="killer_cell" sem="Cell_natural">killer cells</term> and <term id="T4" lex="lymphocyte" sem="Cell_natural">lymphocytes</term> from patients receiving <term id="T5" lex="IL-2_immunotherapy" sem="Other"><term id="T6" lex="IL-2" sem="Protein_molecule">IL-2</term> immunotherapy</term>.</sentence>
<event KT="Investigation" id="E1">
<type class="Positive_regulation"/>
<theme idref="T2"/>
<clue>Transcription factor <clueType>activation</clueType> <clueLoc>in lymphokine activated killer cells</clueLoc> and lymphocytes from patients receiving IL-2 immunotherapy.</clue>
</event>
<event KT="Investigation" id="E29">
<type class="Positive_regulation"/>
<theme idref="T2"/>
<clue>Transcription factor <clueType>activation</clueType> <clueLoc>in</clueLoc> lymphokine activated killer cells and <clueLoc>lymphocytes from patients receiving IL-2 immunotherapy</clueLoc>.</clue>
</event>
<event KT="Other" id="E2">
<type class="Physiological_process"/>
<theme idref="T3"/>
<cause idref="A1"/>
<clue>Transcription factor activation in lymphokine <clueType>activated</clueType> killer cells and lymphocytes from patients receiving IL-2 immunotherapy.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">Administration of the <term id="T7" lex="cytokine_interleukin-2" sem="Protein_molecule">cytokine interleukin-2</term> (<term id="T8" lex="IL-2" sem="Protein_molecule">IL-2</term>) can result in therapeutic benefits for individuals with <term id="T9" lex="renal_cell_carcinoma" sem="Tissue_natural">renal cell carcinoma</term> and <term id="T10" lex="melanoma" sem="Other">melanoma</term>.</sentence>
<event KT="Method" id="E3">
<type class="Artificial_process"/>
<theme idref="T8"/>
<clue><clueType>Administration</clueType> <linkTheme>of</linkTheme> the cytokine interleukin-2 (IL-2) can result in therapeutic benefits for individuals with renal cell carcinoma and melanoma.</clue>
</event>
<sentence id="S3">Here we report an analysis of the <term id="T11" lex="transcription_factor_family" sem="Protein_family_or_group">transcription factor families</term> <term id="T55" lex="AP-1" sem="Protein_complex">AP-1</term>, <term id="T56" lex="SP1" sem="Protein_molecule">Sp1</term>, <term id="T12" lex="NF-kappaB" sem="Protein_complex">NF-kappaB</term>, and <term id="T13" lex="signal_transducers_and_activators_of_transcription" sem="Protein_family_or_group">signal transducers and activators of transcription</term> (<term id="T14" lex="STAT" sem="Protein_family_or_group">STAT</term>) in <term id="T15" lex="cancer_patients&apos;_lymphocytes" sem="Cell_natural">cancer patients&apos; <term id="T16" lex="lymphocyte" sem="Cell_natural">lymphocytes</term></term> before and after <term id="T17" lex="IL-2_immunotherapy" sem="Other"><term id="T18" lex="IL-2" sem="Protein_molecule">IL-2</term> immunotherapy</term>, as assessed by a <term id="T19" lex="gel-shift_assay" sem="Other">gel-shift assay</term>.</sentence>
<sentence id="S4">An in vitro surrogate of <term id="T20" lex="IL-2_immunotherapy" sem="Other"><term id="T21" lex="IL-2" sem="Protein_molecule">IL-2</term> immunotherapy</term> is the incubation of <term id="T22" lex="fresh_peripheral_blood_mononuclear_cell" sem="Cell_natural">fresh peripheral blood mononuclear cells</term> (<term id="T23" lex="PBMC" sem="Cell_natural">PBMC</term>) from <term id="T24" lex="healthy_individual" sem="Multicellular_organism_natural">healthy individuals</term> in <term id="T25" lex="IL-2" sem="Protein_molecule">IL-2</term> for several days, resulting in the production of <term id="T26" lex="lymphokine-activated_killer_(LAK)_activity" sem="Other"><term id="T27" lex="lymphokine" sem="Protein_family_or_group">lymphokine</term>-activated <term id="A2" sem="Cell_natural">killer</term> (LAK) activity</term> in these cultures.</sentence>
<event KT="Method" id="E4">
<type class="Artificial_process"/>
<theme idref="T23"/>
<theme idref="T25"/>
<clue>An in vitro surrogate of IL-2 immunotherapy is the <clueType>incubation</clueType> <linkTheme>of</linkTheme> fresh peripheral blood mononuclear cells (PBMC) from healthy individuals <linkTheme>in</linkTheme> IL-2 <clueTime>for several days</clueTime>, resulting in the production of lymphokine-activated killer (LAK) activity in these cultures.</clue>
</event>
<event KT="Other" id="E5">
<type class="Positive_regulation"/>
<theme idref="E6"/>
<cause idref="E4"/>
<clue>An in vitro surrogate of IL-2 immunotherapy is the incubation of fresh peripheral blood mononuclear cells (PBMC) from healthy individuals in IL-2 for several days, <clueType>resulting in the production</clueType> <linkTheme>of</linkTheme> lymphokine-activated killer (LAK) activity <clueLoc>in these cultures</clueLoc>.</clue>
</event>
<event KT="Other" id="E6">
<type class="Physiological_process"/>
<theme idref="A2"/>
<cause idref="T27"/>
<clue>An in vitro surrogate of IL-2 immunotherapy is the incubation of fresh peripheral blood mononuclear cells (PBMC) from healthy individuals in IL-2 for several days, resulting in the production of lymphokine-<clueType>activated</clueType> killer (LAK) activity in these cultures.</clue>
</event>
<sentence id="S5">One purpose of this study was to describe the profile of <term id="T28" lex="transcription_factor_activation" sem="Other"><term id="A3" sem="Protein_family_or_group">transcription factor</term> activation</term> in these different populations, and assess whether the patterns observed correlated with <term id="T29" lex="functional_difference" sem="Other">functional differences</term> in these cells.</sentence>
<event KT="Investigation" id="E7" uncertainty="doubtful">
<type class="Positive_regulation"/>
<theme idref="A3"/>
<clue>One purpose of this study was <clueKT>to describe</clueKT> the profile of transcription factor <clueType>activation</clueType> <clueLoc>in these different populations</clueLoc>, and assess whether the patterns observed correlated with functional differences in these cells.</clue>
</event>
<sentence id="S6">Prior to in vivo <term id="T30" lex="IL-2" sem="Protein_molecule">IL-2</term> administration, the typical binding pattern of <term id="T31" lex="transcription_factor" sem="Protein_family_or_group">transcription factors</term> in <term id="T32" lex="PBMC" sem="Cell_natural">PBMC</term> from patients resembled that seen in fresh <term id="T33" lex="PBMC" sem="Cell_natural">PBMC</term> from <term id="T34" lex="healthy_individual" sem="Multicellular_organism_natural">healthy individuals</term>.</sentence>
<event KT="Method" id="E8">
<type class="Artificial_process"/>
<theme idref="T30"/>
<clue>Prior to in vivo IL-2 <clueType>administration</clueType>, the typical binding pattern of transcription factors in PBMC from patients resembled that seen in fresh PBMC from healthy individuals.</clue>
<comment>NO THEME</comment></event>
<event KT="Analysis" id="E9">
<type class="Binding"/>
<theme idref="T31"/>
<clue><clueTime>Prior to in vivo IL-2 administration</clueTime>, the <clueKT>typical</clueKT> <clueType>binding</clueType> pattern <linkTheme>of</linkTheme> transcription factors <clueLoc>in PBMC from patients</clueLoc> resembled that seen in fresh PBMC from healthy individuals.</clue>
</event>
<event KT="Other" id="E10">
<type class="Binding"/>
<theme idref="T31"/>
<clue>Prior to in vivo IL-2 administration, the typical <clueType>binding</clueType> pattern <linkTheme>of</linkTheme> transcription factors in PBMC from patients resembled that seen <clueLoc>in fresh PBMC from healthy individuals</clueLoc>.</clue>
</event>
<sentence id="S7">Over a 3-week course of <term id="T35" lex="IL-2" sem="Protein_molecule">IL-2</term> therapy, in most <term id="T36" lex="patient" sem="Multicellular_organism_natural">patients</term> the binding patterns of <term id="T37" lex="AP-1" sem="Protein_molecule">AP-1</term> , <term id="T38" lex="Sp1" sem="Protein_molecule">Sp1</term>, and <term id="T39" lex="NF-kappaB" sem="Protein_complex">NF-kappaB</term> proteins changed to resemble those seen in <term id="T40" lex="PBMC" sem="Cell_natural">PBMC</term> activated by <term id="T41" lex="IL-2" sem="Protein_molecule">IL-2</term> in vitro.</sentence>
<event KT="Analysis" id="E11">
<type class="Positive_regulation"/>
<theme idref="E14"/>
<cause idref="T35"/>
<clue><clueTime>Over a 3-week course</clueTime> <linkCause>of</linkCause> IL-2 therapy, <clueKT>in most</clueKT> patients the binding patterns of AP-1 , Sp1, and NF-kappaB proteins <clueType>changed</clueType> to resemble those seen in PBMC activated by IL-2 in vitro.</clue>
</event>
<event KT="Analysis" id="E12">
<type class="Positive_regulation"/>
<theme idref="E15"/>
<cause idref="T35"/>
<clue><clueTime>Over a 3-week course</clueTime> <linkCause>of</linkCause> IL-2 therapy, <clueKT>in most</clueKT> patients the binding patterns of AP-1 , Sp1, and NF-kappaB proteins <clueType>changed</clueType> to resemble those seen in PBMC activated by IL-2 in vitro.</clue>
</event>
<event KT="Analysis" id="E13">
<type class="Positive_regulation"/>
<theme idref="E16"/>
<cause idref="T35"/>
<clue><clueTime>Over a 3-week course</clueTime> <linkCause>of</linkCause> IL-2 therapy, <clueKT>in most</clueKT> patients the binding patterns of AP-1 , Sp1, and NF-kappaB proteins <clueType>changed</clueType> to resemble those seen in PBMC activated by IL-2 in vitro.</clue>
</event>
<event KT="Other" id="E14">
<type class="Binding"/>
<theme idref="T37"/>
<clue>Over a 3-week course of IL-2 therapy, in most patients the <clueType>binding</clueType> patterns <linkTheme>of</linkTheme> AP-1 , Sp1, and NF-kappaB proteins changed to resemble those seen in PBMC activated by IL-2 in vitro.</clue>
</event>
<event KT="Other" id="E15">
<type class="Binding"/>
<theme idref="T38"/>
<clue>Over a 3-week course of IL-2 therapy, in most patients the <clueType>binding</clueType> patterns <linkTheme>of</linkTheme> AP-1 , Sp1, and NF-kappaB proteins changed to resemble those seen in PBMC activated by IL-2 in vitro.</clue>
</event>
<event KT="Other" id="E16">
<type class="Binding"/>
<theme idref="T39"/>
<clue>Over a 3-week course of IL-2 therapy, in most patients the <clueType>binding</clueType> patterns <linkTheme>of</linkTheme> AP-1 , Sp1, and NF-kappaB proteins changed to resemble those seen in PBMC activated by IL-2 in vitro.</clue>
</event>
<event KT="Other" id="E17">
<type class="Binding"/>
<theme idref="T37"/>
<clue>Over a 3-week course of IL-2 therapy, in most patients the <clueType>binding</clueType> patterns <linkTheme>of</linkTheme> AP-1 , Sp1, and NF-kappaB proteins changed to resemble those seen <clueLoc>in PBMC activated by IL-2 in vitro</clueLoc>.</clue>
</event>
<event KT="Other" id="E18">
<type class="Binding"/>
<theme idref="T38"/>
<clue>Over a 3-week course of IL-2 therapy, in most patients the <clueType>binding</clueType> patterns <linkTheme>of</linkTheme> AP-1 , Sp1, and NF-kappaB proteins changed to resemble those seen <clueLoc>in PBMC activated by IL-2 in vitro</clueLoc>.</clue>
</event>
<event KT="Other" id="E19">
<type class="Binding"/>
<theme idref="T39"/>
<clue>Over a 3-week course of IL-2 therapy, in most patients the <clueType>binding</clueType> patterns <linkTheme>of</linkTheme> AP-1 , Sp1, and NF-kappaB proteins changed to resemble those seen <clueLoc>in PBMC activated by IL-2 in vitro</clueLoc>.</clue>
</event>
<event KT="Other" id="E20">
<type class="Physiological_process"/>
<theme idref="T40"/>
<cause idref="T41"/>
<clue>Over a 3-week course of IL-2 therapy, in most patients the binding patterns of AP-1 , Sp1, and NF-kappaB proteins changed to resemble those seen in PBMC <clueType>activated</clueType> <linkCause>by</linkCause> IL-2 in vitro.</clue>
</event>
<sentence id="S8">However, the cells obtained from <term id="T42" lex="IL-2-treated_patient" sem="Other"><term id="T43" lex="IL-2" sem="Protein_molecule">IL-2</term>-treated <term id="T44" lex="patient" sem="Multicellular_organism_natural">patients</term></term> did not have low-level constitutive expression of <term id="T45" lex="STAT_binding_factor" sem="Protein_family_or_group">STAT binding factors</term> as did <term id="T46" lex="LAK_cell" sem="Protein_family_or_group">LAK cells</term>.</sentence>
<event Manner="Low" Polarity="Negative" assertion="non-exist" id="E21">
<type class="Gene_expression"/>
<theme idref="T45"/>
<clue>However, <clueLoc>the cells obtained from IL-2-treated patients</clueLoc> did <cluePolarity>not</cluePolarity> have <clueManner>low-level</clueManner> constitutive <clueType>expression</clueType> <linkTheme>of</linkTheme> STAT binding factors as did LAK cells.</clue>
</event>
<event Manner="Low" id="E23">
<type class="Gene_expression"/>
<theme idref="T45"/>
<clue>However, the cells obtained from IL-2-treated patients did not have <clueManner>low-level</clueManner> constitutive <clueType>expression</clueType> <linkTheme>of</linkTheme> STAT binding factors as did <clueLoc>LAK cells</clueLoc>.</clue>
<comment>CAUTION: SEE</comment></event>
<sentence id="S9">When these patient cells were further stimulated by <term id="T47" lex="IL-2_in_vitro" sem="Other"><term id="T48" lex="IL-2" sem="Protein_molecule">IL-2</term> in vitro</term>, additional differences in <term id="T49" lex="STAT_induction" sem="Other"><term id="T50" lex="STAT" sem="Protein_family_or_group">STAT</term> induction</term> patterns were noted.</sentence>
<event id="E24">
<type class="Physiological_process"/>
<theme idref="T40"/>
<cause idref="T48"/>
<clue>When <corefTheme>these patient cells</corefTheme> were further <clueType>stimulated</clueType> <linkCause>by</linkCause> IL-2 in vitro, additional differences in STAT induction patterns were noted.</clue>
</event>
<event KT="Analysis" id="E25">
<type class="Positive_regulation"/>
<theme idref="T50"/>
<clue>When these patient cells were further stimulated by IL-2 in vitro, additional differences in STAT <clueType>induction</clueType> patterns were <clueKT>noted</clueKT>.</clue>
<comment>NER: T49 mod</comment></event>
<sentence id="S10">These data provide further information on the <term id="A4" sem="Other">molecular events</term> occurring in <term id="T51" lex="immune_cell" sem="Cell_natural">immune cells</term> generated through in vivo and in vitro administration of <term id="T52" lex="IL-2" sem="Protein_molecule">IL-2</term>, and further document that there is not a precise congruence between <term id="T53" lex="PBMC" sem="Cell_natural">PBMC</term> activated in vivo and in vitro by <term id="T54" lex="IL-2" sem="Protein_molecule">IL-2</term>.</sentence>
<event KT="Method" id="E26">
<type class="Artificial_process"/>
<theme idref="T52"/>
<clue>These data provide further information on the molecular events occurring in immune cells generated through in vivo and in vitro <clueType>administration</clueType> <linkCause>of</linkCause> IL-2, and further document that there is not a precise congruence between PBMC activated in vivo and in vitro by IL-2.</clue>
</event>
<event KT="Analysis" id="E27">
<type class="Positive_regulation"/>
<theme idref="A4"/>
<cause idref="E26"/>
<clue>These data <clueKT>provide</clueKT> further <clueKT>information</clueKT> on the molecular events <clueType>occurring</clueType> <clueLoc>in immune cells</clueLoc> <linkCause>generated through</linkCause> in vivo and in vitro administration of IL-2, and further document that there is not a precise congruence between PBMC activated in vivo and in vitro by IL-2.</clue>
</event>
<event KT="Analysis" id="E28">
<type class="Physiological_process"/>
<theme idref="T53"/>
<cause idref="T54"/>
<clue>These data provide further information on the molecular events occurring in immune cells generated through in vivo and in vitro administration of IL-2, and further <clueKT>document</clueKT> that there is not a precise congruence between PBMC <clueType>activated</clueType> in vivo and in vitro <linkCause>by</linkCause> IL-2.</clue>
</event>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
